#$gern

[abrcapfinancial-blog]

EARNING UPDATE $GERN Geron Corporation for quarter ending q_Jun18 - Revenue fell, Margins contracted

EARNING UPDATE $GERN Geron Corporation for quarter ending q_Jun18 – Revenue fell, Margins contracted

[s2If !current_user_can(access_s2member_level0)]Please login to read the earning update on GERN [lwa][/s2If][s2If current_user_can(access_s2member_level0)]Geron Corporation reported earnings (EPS) of -0.04 per share for the quarter ending q_Jun18. This is vis-vis -0.04 per share for the previous quarter ending q_Mar18, a decline of 0 %. Compared to last year same quarter (q_Jun17), earnings grew…

View On WordPress

[adamfeuerstein]

The ASH 2014 Abstract Stampede Just Happened

Acting just like the cute goats, healthcare investors rushed the web site of the American Society of Clinical Hematology (ASH) on Thursday morning to download hundreds of research abstracts describing new clinical data on drugs for blood cancers.

Naturally, biotech and drug stocks react almost instantly to the frenzied interpretation of the ASH abstracts. It doesn't matter that the data in the abstracts is preliminary and will be obsolete in a month's time when updates are presented at the ASH annual meeting in early December. 

Wall Street demands instant winners and losers.Here's how some key blood-cancer biotech stocks are trading Thursday:

And a few more: